Skip to main content Accessibility help
Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-21T20:57:35.490Z Has data issue: false hasContentIssue false

Chapter 15 - Drugs to Treat Substance Use Disorders

from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

Peter M. Haddad
Hamad Medical Corporation, Qatar
David J. Nutt
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access


This chapter deals with drugs used to treat substance use disorders (SUDs) due to nicotine, alcohol, opioids and benzodiazepines. A final section briefly considers other common drugs of misuse.

Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Agabio, R, Sinclair, J, Addolorato, G, et al. (2018). Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry, 5, 957960.Google Scholar
Amato, L, Minozzi, S, Davoli, M (2011). Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev, (6), CD008537.Google Scholar
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.Google Scholar
Anthenelli, RM, Benowitz, NL, West, R, et al. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 387, 25072520.CrossRefGoogle Scholar
Bakker, A, Streel, E (2016). Benzodiazepine maintenance in opiate substitution treatment: good or bad? A retrospective primary care case-note review. J Psychopharmacol, 31, 6266.CrossRefGoogle ScholarPubMed
Beck, T, Haasen, C, Verthein, U, et al. (2014). Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction, 109, 617626.CrossRefGoogle ScholarPubMed
Bordia, T, Hrachova, M, Chin, M, McIntosh, JM, Quik, M (2012). Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther, 342, 327334.CrossRefGoogle ScholarPubMed
Burns, L, Gisev, N, Larney, S, et al. (2015). A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction, 110, 646655.Google Scholar
Cahill, K, Lindson-Hawley, N, Thomas, KH, Fanshawe, TR, Lancaster, T (2016). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, (5), CD006103.Google Scholar
Chick, J (1999). Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf, 20, 427435.Google Scholar
Chick, J, Nutt, DJ (2012). Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol, 26, 205212.CrossRefGoogle ScholarPubMed
Chick, J, Gough, K, Falkowski, W, et al. (1992). Disulfiram treatment of alcoholism. Br J Psychiatry, 161, 8489.CrossRefGoogle ScholarPubMed
Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017). Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health.Google Scholar
Coe, JW, Brooks, PR, Vetelino, MG, et al. (2005). Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 48, 34743477.CrossRefGoogle ScholarPubMed
Colasanti, A, Rabiner, E, Lingford-Hughes, A, Nutt, D (2011). Opioids and anxiety. J Psychopharmacol, 25, 14151433.Google Scholar
Coleman, T, Chamberlain, C, Davey, M-A, Cooper, SE, Leonardi-Bee, J (2015). Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev, (12), CD010078.Google Scholar
Darke, S, Ross, J, Mills, K, et al. (2010). Benzodiazepine use among heroin users: baseline use, current use and clinical outcome. Drug Alcohol Rev, 29, 250255.Google Scholar
Darker, CD, Sweeney, BP, Barry, JM, Farrell, MF, Donnelly-Swift, E (2015). Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev, (5), CD009652.Google Scholar
de Beaurepaire, R, Sinclair, JMA, Heydtmann, M, et al. (2018). The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Front Psychiatry, 9, 708.Google Scholar
Degenhardt, L, Charlson, F, Mathers, B, et al. (2014a). The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction, 109, 13201333.CrossRefGoogle ScholarPubMed
Degenhardt, L, Larney, S, Randall, D, Burns, L, Hall, W (2014b). Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction, 109, 9099.CrossRefGoogle Scholar
Di Ciano, P, Guranda, M, Lagzdins, D, et al. (2016). Varenicline-induced elevation of dopamine in smokers: a preliminary [11C]-(+)-PHNO PET study. Neuropsychopharmacology, 41, 15131520.Google Scholar
Donoghue, K, Elzerbi, C, Saunders, R, et al. (2015). The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta‐analysis. Addiction, 110, 920930.Google Scholar
Ebbert, JO, Hughes, JR, West, RJ, et al. (2015). Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA, 313, 687694.CrossRefGoogle ScholarPubMed
Elholm, B, Larsen, K, Hornnes, N, Zierau, F, Becker, U (2011). Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting. Alcohol Alcohol, 46, 318323.Google Scholar
European Medicines Agency (2017). Alcover (granules in sachet) and associated names. London: European Medicines Agency.Google Scholar
Garcia-Borreguero, D, Bronisch, T, Apelt, S, Yassouridis, A, Emrich, HM (1991). Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci, 241, 145150.Google Scholar
Goodwin, G, Haddad, P, Ferrier, I, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30, 495553.Google Scholar
Gossop, M (1990). The development of a short opiate withdrawal scale (SOWS). Addict Behav, 15, 487490.Google Scholar
Gowing, L, Farrell, M, Ali, R, White, JM (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev, (5), CD002024.Google Scholar
Haber, P, Lintzeris, N, Proude, E, Lopatko, O (2009). Guidelines for the Treatment of Alcohol Problems. Canberra: Commonwealth of Australia.Google Scholar
Hajak, G, Müller, WE, Wittchen, HU, Pittrow, D, Kirch, W (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction, 98, 13711378.CrossRefGoogle ScholarPubMed
Harper, CG, Giles, M, Finlay-Jones, R (1986). Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry, 49, 341345.Google Scholar
Hartmann-Boyce, J, McRobbie, H, Bullen, C, et al. (2016). Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev, (9), CD010216.Google Scholar
Hartmann-Boyce, J, Chepkin, SC, Ye, W, Bullen, C, Lancaster, T (2018). Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev, (5), CD000146.Google ScholarPubMed
Hasin, DS, Stinson, FS, Ogburn, E, Grant, BF (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry, 64, 830842.Google Scholar
Hay, G, Rael dos Santos, A, Swithenbank, Z (2017). Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use, 2014/15: Sweep 11 Report. Public Health England. Liverpool: Public Health Institute, John Moores University.Google Scholar
Hser, Y-I, Evans, E, Huang, D, et al. (2016). Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction, 111, 695705.CrossRefGoogle Scholar
Hughes, JR, Stead, LF, Hartmann-Boyce, J, Cahill, K, Lancaster, T (2014). Antidepressants for smoking cessation. Cochrane Database Syst Rev, (1), CD000031.Google Scholar
Jones, HE, Kaltenbach, K, Heil, SH, et al. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New Engl J Med, 363, 23202331.Google Scholar
Kalk, NJ, Lingford-Hughes, AR (2014). The clinical pharmacology of acamprosate. Br J Clin Pharmacol, 77, 315323.CrossRefGoogle ScholarPubMed
Koob, GF, Le Moal, M (2006). Nicotine. In Koob, GF, Le Moal, M, eds., Neurobiology of Addiction. Amsterdam: Elsevier.Google ScholarPubMed
Kosten, TR, George, TP (2002). The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect, 1, 1320.CrossRefGoogle ScholarPubMed
Kotz, D, Viechtbauer, W, Simpson, C, et al. (2015). Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med, 3, 761768.Google Scholar
Larney, S, Gowing, L, Mattick, RP, et al. (2014). A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev, 33, 115128.Google Scholar
Lasser, K, Boyd, J, Woolhandler, S, et al. (2000). Smoking and mental illness: a population-based prevalence study. JAMA, 284, 26062610.Google Scholar
Law, FD, Diaper, AM, Melichar, JK, et al. (2017). Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: a randomised controlled trial of low dose short-term opiate-dependent individuals. J Psychopharamcol, 31, 10461055.Google Scholar
Lejoyeux, M, Lehert, P (2011). Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol, 46, 6167.CrossRefGoogle ScholarPubMed
Liebrenz, M, Boesch, L, Stohler, R, Caflisch, C (2010). Agonist substitution – a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction, 105, 18701874.CrossRefGoogle ScholarPubMed
Lingford-Hughes, AR, Welch, S, Peters, L, Nutt, DJ (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol, 26, 899952.Google Scholar
Lishman, W (1998). Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. Oxford: Blackwell Science, pp. 315323.Google Scholar
Mann, K, Torup, L, Sørensen, P, et al. (2016). Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol, 26, 19411949.Google Scholar
Marsch, LA, Moore, SK, Borodovsky, JT, et al. (2016). A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction, 111, 14061415.Google Scholar
Mattick, RP, Breen, C, Kimber, J, Davoli, M (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev, (3), CD002209.Google Scholar
Mattick, RP, Breen, C, Kimber, J, Davoli, M (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.Google Scholar
McNeill, A, Brose, LS, Calder, R, Bauld, L, Robson, D (2018). Evidence review of e-cigarettes and heated tobacco products. A report commissioned by Public Health England. London: Public Health England.Google Scholar
MHRA (2006). Current Problems in Pharmacovigilance, Vol. 31. London: Medicines and Healthcare products Regulatory Agency.Google Scholar
Minozzi, S, Amato, L, Vecchi, S, Davoli, M (2010). Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev, (3), CD005064.Google Scholar
Minozzi, S, Amato, L, Vecchi, S, et al. (2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev, (4), CD001333.Google Scholar
Montgomery, AJ, Lingford‐Hughes, AR, Egerton, A, Nutt, DJ, Grasby, PM (2007). The effect of nicotine on striatal dopamine release in man: a [11C] raclopride PET study. Synapse, 61, 637645.Google Scholar
National Institute for Health and Care Excellence (NICE) (2007a). Methadone and buprenorphine for the management of opioid dependence. Technology appraisal guidance [TA114]. Manchester: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2007b). Drug misuse: opiate detoxification. Clinical guideline [CG52]. Manchester: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2007c). Naltrexone for the management of opioid dependence. Technology appraisal guidance [TA115]. Manchester: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2010a). Alcohol-use disorders: diagnosis and management of physical complications. Clinical guideline [CG100]. Manchester: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2010b). Smoking: stopping in pregnancy and after childbirth. Public health guideline [PH26]. Manchester: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2011). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. Clinical guideline [CG115]. Manchester: National Institute for Health and Care Excellence.Google Scholar
Nesvåg, R, Knudsen, GP, Bakken, IJ, et al. (2015). Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol, 50, 12671276.Google Scholar
Nielsen, S, Dietze, P, Lee, N, Dunlop, A, Taylor, D (2007). Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction, 102, 616622.Google Scholar
Nolan, S, Dias Lima, V, Fairbairn, N, et al. (2014). The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction, 109, 20532059.Google Scholar
Nosyk, B, Sun, H, Evans, E, et al. (2012). Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction, 107, 16211629.Google Scholar
Novel Psychoactive Treatment UK Network (NEPTUNE) (2015). Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances. (online). London. (last accessed 19.2.18).Google Scholar
Nutt, DJ, Lingford-Hughes, A, Chick, J (2012). Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments? J Psychopharmacol, 26, 199204.Google Scholar
Nutt, DJ, Lingford-Hughes, A, Erritzoe, D, Stokes, P (2015). The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci, 16, 305312.Google Scholar
Office for National Statistics (2017a). Deaths related to drug poisoning in England and Wales: 2016 registrations. Statistical Bulletin. London: Office for National Statistics.Google Scholar
Office for National Statistics (2017b). Drug misuse: findings from the 2016/17 CSEW. London: Home Office.Google Scholar
Pathan, H, Williams, J (2012). Basic opioid pharmacology: an update. Br J Pain, 6, 1116.CrossRefGoogle ScholarPubMed
Petrakis, IL, Poling, J, Levinson, C, et al. (2005). Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry, 57, 11281137.Google Scholar
Pierce, M, Bird, SM, Hickman, M, et al. (2016). Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction, 111, 298308.Google Scholar
Public Health England (2016). Shooting up: infections among people who injected drugs in the UK, 2015. An update: November 2016. London: Public Health England.Google Scholar
Public Health England (2017a). Take-home naloxone for opioid overdose in people who use drugs. London: Public Health England.Google Scholar
Public Health England (2017b). Adult substance misuse statistics from the National Drug Treatment Monitoring System (NDTMS). London: Public Health England.Google Scholar
Public Health England (2018). Adult substance misuse statistics from the National Drug Treatment Monitoring System (NDTMS). London: Public Health England.Google Scholar
Quelch, DR, Mick, I, McGonigle, J, et al. (2017). Nalmefene reduces reward anticipation in alcohol dependence: an experimental functional magnetic resonance imaging study. Biol Psychiatry, 81, 941948.Google Scholar
Rehm, J, Shield, K, Gmel, G, Rehm, M, Frick, U (2013). Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol, 23, 8997.Google Scholar
Reitsma, M (2017). Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, 389, 18851906.Google Scholar
Robertson, JR, Raab, GM, Bruce, M, et al. (2006). Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction, 101, 17521759.Google Scholar
Rösner, S, Hackl‐Herrwerth, A, Leucht, S, et al. (2010). Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev, (12), CD001867.Google Scholar
Ross, J, Ross, J, Teesson, M, et al. (2005). The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev, 24, 411418.Google Scholar
Saunders, JB, Aasland, OG, Amundsen, A, Grant, M (1993). Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption – I. Addiction, 88, 349362.CrossRefGoogle ScholarPubMed
Sechi, G, Serra, A (2007). Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol, 6, 442455.Google Scholar
Senbanjo, R, Wolff, K, Marshall, J (2007). Excessive alcohol consumption is associated with reduced quality of life among methadone patients. Addiction, 102, 257263.Google Scholar
Sinclair, JMA, Latifi, AH, Latifi, AW (2008). Co-morbid substance misuse in psychiatric inpatients: prevalence and association with length of inpatient stay. J Psychopharmacol, 22, 9298.Google Scholar
Sinclair, JM, Chambers, SE, Shiles, CJ, Baldwin, DS (2016). Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf, 39, 627645.Google Scholar
Sordo, L, Barrio, G, Bravo, MJ, et al. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.Google Scholar
Stapleton, J, West, R, Hajek, P, et al. (2013). Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction, 108, 21932201.CrossRefGoogle ScholarPubMed
Sterling, LH, Windle, SB, Filion, KB, Touma, L, Eisenberg, MJ (2016). Varenicline and adverse cardiovascular events: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc, 5, e002849.CrossRefGoogle ScholarPubMed
Stockwell, T, Murphy, D, Hodgson, R (1983). The severity of alcohol dependence questionnaire: its use, reliability and validity. Br J Addict, 78, 145155.Google Scholar
Strang, J, Groshkova, T, Uchtenhagen, A, et al. (2015). Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry, 207, 514.Google Scholar
Sullivan, JT, Sykora, K, Schneiderman, J, Naranjo, CA, Sellers, EM (1989). Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict, 84, 1353–1357.Google Scholar
Sun, EC, Dixit, A, Humphreys, K, et al. (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ, 356, j760.Google Scholar
Sweizer, E, Rickets, K, Case, WG, Greenblatt, DJ (1991). Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry, 48, 448452.Google Scholar
Swift, RM (2013). Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry, 73, 700701.Google Scholar
Toftdahl, NG, Nordentoft, M, Hjorthøj, C (2016). Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol, 51, 129140.Google Scholar
Ulrichsen, J, Nielsen, MK, Ulrichsen, M (2010). Disulfiram in severe alcoholism – an open controlled study. Nord J Psychiatry, 64, 356362.Google Scholar
Umhau, JC, Momenan, R, Schwandt, ML, et al. (2010). Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry, 67, 10691077.Google Scholar
Victorri-Vigneau, C, Dailly, E, Veyrac, G, Jolliet, P (2007). Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol, 64, 198209.Google Scholar
Weaver, T, Madden, P, Charles, V, et al. (2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry, 183, 304313.Google Scholar
Wesson, DR, Ling, W (2003). The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs, 35, 253259.Google Scholar
Wilde, MI, Wagstaff, AJ (1997). Acamprosate. Drugs, 53, 10381053.Google Scholar
World Health Organization (1992). ICD-10: International Statistical Classification of Diseases and Related Health Problems. Geneva: World Health Organization.Google Scholar
World Health Organization (2014). Global status report on alcohol and health 2014. Available at: (last accessed 11.8.19).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats